Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
US Army
McKesson
McKinsey
Daiichi Sankyo
Express Scripts
Dow
Boehringer Ingelheim
Teva

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PREGNYL

« Back to Dashboard

Clinical Trials for Pregnyl

Trial ID Title Status Sponsor Phase Summary
NCT00415766 Comparison Between Recombinant Versus Urinary hCG for Ovulation Induction in High Responders Active, not recruiting Eugonia Phase 4 The purpose of this study is to compare the clinical outcomes of recombinant human chorionic gonadotrophin (rHCG) and urinary HCG (uHCG) in patients undergoing IVF cycles.
NCT00415792 Comparison Between hCG and GnRH Agonist for Ovulation Induction in Patients With High Response to IVF Drugs Unknown status Eugonia Phase 4 hCG and GnRH agonist can be used to induce final oocyte maturation and ovulation in IVF cycles. These two approaches will be compared in this study in terms of pregnancy rates and embryological data using patients with hyper-response to IVF drugs.
NCT00627406 Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles Completed Regionshospitalet Viborg, Skive Phase 4 The purpose of this study is to possibly further improve the clinical outcome and explore the incidence of OHSS in patients, who have final oocyte maturation with GnRHa (Buserelin) in GnRH antagonist IVF/ICSI cycles
NCT00809107 Frozen Embryo Transfer (FET) in Natural Cycles or in Natural Cycles Controlled by Human Chorionic Gonadotropin (hCG) Administration Completed Universitair Ziekenhuis Brussel N/A The rational of the study is to assess the implantation, pregnancy and live birth rates after the transfer of frozen- thawed embryos in natural cycles with spontaneous Luteinizing Hormone (LH)/Progesterone rise or in natural cycles controlled by human chorionic gonadotropin (hCG) for final oocyte maturation and ovulation.
NCT00823004 Antagonist/Letrozole in Poor Responders Completed Yazd Research & Clinical Center for Infertility Phase 1/Phase 2 Failure to respond to controlled ovarian hyperstimulation (COH) is still a major concern in assisted reproduction and there is no consensus on the ovarian stimulation choice regime for poor responders. Aim: To evaluate and compare the efficacy of a microdose GnRH agonist flare (MF) and a GnRH antagonist/letrozole (A/L) protocols in poor responders undergoing in vitro fertilization (IVF). Methods: One hundred eighty poor responder patients will be randomized to an ovarian stimulation protocol with either a MF or a letrozole and high dose FSH/hMG and flexible GnRH antagonist protocol.
NCT00823121 Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification Unknown status Yazd Research & Clinical Center for Infertility Phase 1/Phase 2 Cryopreservation of all embryos and transferring them subsequently in assisted reproductive technology (ART) cycles to improve outcome.
NCT00839319 HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 1/Phase 2 The purpose of this investigational study is to determine how much male hormone, testosterone, is necessary to maintain sperm production in the testis. This knowledge will be used to help in the development of a safe male hormonal contraception.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Pregnyl

Condition Name

Condition Name for Pregnyl
Intervention Trials
Infertility 10
Polycystic Ovary Syndrome 5
Invitro Fertilization 2
Female Infertility 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Pregnyl
Intervention Trials
Infertility 12
Polycystic Ovary Syndrome 5
Syndrome 3
Infertility, Female 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Pregnyl

Trials by Country

Trials by Country for Pregnyl
Location Trials
Egypt 8
Greece 4
Belgium 4
United States 3
Iran, Islamic Republic of 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Pregnyl
Location Trials
Connecticut 1
Washington 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Pregnyl

Clinical Trial Phase

Clinical Trial Phase for Pregnyl
Clinical Trial Phase Trials
Phase 4 11
Phase 3 1
Phase 2/Phase 3 5
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Pregnyl
Clinical Trial Phase Trials
Completed 13
Recruiting 8
Unknown status 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Pregnyl

Sponsor Name

Sponsor Name for Pregnyl
Sponsor Trials
University of Athens 3
Universitair Ziekenhuis Brussel 3
Cairo University 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Pregnyl
Sponsor Trials
Other 39
Industry 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
McKesson
Colorcon
Cipla
Cantor Fitzgerald
Merck
Accenture
Fuji
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.